Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses

Journal of Virology

Volumn 78, Issue 17, 2004, Pages 9190-9202

  Trujillo, J D ^a   Kumpula McWhirter, N M ^a   Hotzel K J ^a   Gonzalez, M ^a   Cheevers, W P ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPITOPE; HISTIDINE; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; POLYPEPTIDE; RECOMBINANT PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CAPRINE ARTHRITIS ENCEPHALITIS VIRUS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS REACTION; ENCEPHALITIS VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; GOAT; IMMUNIZATION; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS ENCEPHALITIS; VIRUS ENVELOPE; VIRUS INFECTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ARTHRITIS-ENCEPHALITIS VIRUS, CAPRINE; BLOTTING, WESTERN; CROSS REACTIONS; GLYCOSYLATION; GOATS; IMMUNODOMINANT EPITOPES; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 4143092625     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.17.9190-9202.2004     Document Type: Article

References (61)

1. Andresdottir, V., R. Skraban, S. Matthiasdottir, R. Lutley, G. Agnarsdoltir, and H. Thorsteinsdottir. 2002. Selection of antigenic variants in maedi-visna virus infection. J. Gen. Virol. 83:2543-2551.
2. Andrus, L., A. M. Prince, I. Bernal, P. McCormack, D. H. Lee, M. K. Gorny, and S. Zolla-Pazner. 1998. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J. Infect. Dis. 177:889-897.
3. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, B. J. Bernaeky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, Y. Lu, J. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
4. Barnett, S. W., S. Lu, I. Srivastava, S. Cherpelis, A. Gettie, J. Blanchard, S. Wang, I. Mboudjeka, L. Leung, V. Lian, A. Fong, C. Buckner, A. Ly, S. Hilt, J. Ulmer, C. T. Wild, J. R. Mascola, and L. Stamatatos. 2001. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:5526-5540.
5. Bertoni, G., C. Hertig, M. L. Zahno, H. R. Vogt, S. Dufour, P. Cordano, E. Peterhans, W. P. Cheevers, P. Sonigo, and G. Pancino. 2000. B-cell epitopes of the envelope glycoprotein of caprine arthritis-encephalitis virus and antibody response in infected goats. J. Gen. Virol. 81:2929-2940.
6. Blasco, R., and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162.
7. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Berman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013.
8. Bures, R., A. Gaitan, T. Zhu, C. Graziosi, K. M. McGrath, J. Tartaglia, P. Caudrelier, R. El Habib, M. Klein, A. Lazzarin, D. M. Stablein, M. Deers, L. Corey, M. L. Greenberg, D. H. Schwartz, and D. C. Montefiori. 2000. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 16:2019-2035.
9. Burns, D. P., and R. C. Desrosiers. 1994. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. Curr. Top. Microbiol. Immunol. 188:185-219.
10. Cheevers, W. P., D. P. Knowles, T. C. McGuire, D. R. Cunningham, D. S. Adams, and J. R. Gorham. 1988. Chronic disease in goats orally infected with two isolates of the caprine arthritis-encephalitis lentivirus. Lab. Investig. 58:510-517.
11. Cheevers, W. P., D. P. Knowles, Jr., and L. K. Norton. 1991. Neutralization-resistant antigenic variants of caprine arthritis-encephalitis lentivirus associated with progressive arthritis. J. Infect. Dis. 164:679-685.
12. Crawford, T. B., D. S. Adams, W. P. Cheevers, and L. C. Cork. 1980. Chronic arthritis in goats caused by a retrovirus. Science 207:997-999.
13. Earl, P. L., R. W. Doms, and B. Moss. 1990. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 87:648-652.
14. Garrity, R. R., G. Rimmelzwaan, A. Minassian, W. P. Tsai, G. Lin, J. J. de Jong, J. Goudsmit, and P. L. Nara. 1997. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159:279-289.
15. Haigwood, N. L., P. L. Nara, E. Brooks, G. A. Van Nest, G. Ott, K. W. Higgins, N. Dunlop, C. J. Scandella, J. W. Eichberg, and K. S. Steimer. 1992. Native but not recombinant human immnunodeficiency virus type 1 gp120 generates broad-sped rum neutralizing antibodies in baboons. J. Virol. 66:172-182.
16. Ho, D. D., M. G. Sarngadharan, M. S. Hirsch, R. T. Schooley, T. R. Rota, R. C. Kennedy, T. C. Chanh, and V. L. Sato. 1987. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61:2024-2028.
17. Hötzel, I., and W. P. Cheevers. 2001. Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins. J. Virol. 75:2014-2018.
18. Hötzel, I., and W. P. Cheevers. 2003. Caprine arthritis-encephalitis virus envelope surface glycoprotein regions interacting with the transmembrane glycoprotein: structural and functional parallels with human immunodeficiency virus type 1 gp120. J. Virol. 77:11578-11587.
19. Hötzel, I., N. Kumpula-McWhirter, and W. P. Cheevers. 2002. Rapid evolution of two discrete regions of the caprine arthritis-encephalitis virus envelope surface glycoprotein during persistent infection. Virus Res. 84:17-25.
20. Jeffs, S. A., C. Shotton, P. Balfe, and J. A. McKealing. 2002. Truncated gp!20 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J. Gen. Virol. 83:2723-2732.
21. Johnson, G. C., A. F. Barbet, P. Klevjer-Anderson, and T. C. McGuire. 1983. Preferential immune response to virion surface glycoproteins by caprine arthritis-encephalitis virus-infected goats. Infect. Immun. 41:657-665.
22. Kemp, R. K., D. P. Knowles, L. L. Perry, T. C. McGuire, T. E. Besser, and W. P. Cheevers. 2000. Crossreactive neutralizing antibodies induced by immunization with caprine arthritis-encephalitis virus surface glycoprotein. Vaccine 18:1282-1287.
23. Kim, Y. B., D. P. Han, C. Cao, and M. W. Cho. 2003. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 305:124-137.
24. Klevjer-Anderson, P., and W. P. Cheevers. 1981. Characterization of the infection of caprine synovial membrane cells by the retrovirus caprine arthritis-encephalitis virus. Virology 110:113-119.
25. Klevjer-Anderson, P., and T. C. McGuire. 1982. Neutralizing antibody response of rabbits and goats to caprine arthritis-encephalitis virus. Infect. Immun. 38:455-461.
26. Knowles, D., Jr., W. Cheevers, T. McGuire, T. Stem, and J. Gorham. 1990. Severity of arthritis is predicted by antibody response to gp135 in chronic infection with caprine arthritis-encephalitis virus. J. Virol. 64:2396-2398.
27. Knowles, D. P., Jr., W. P. Cheevers, T. C. McGuire, A. L. Brassfield, W. G. Hut-wood, and T. A. Stem. 1991. Structure and genetic variability of envelope glycoproteins of two antigenic variants of caprine arthritis-encephalitis lentivirus. J. Virol. 65:5744-5750.
28. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
29. Lichtensteiger, C. A., D. P. Knowles, Jr., T. C. McGuire, and W. P. Cheevers. 1991. Recombinant gp135 envelope glycoproteins of caprine arthritis-encephalitis lentivirus variants inhibit homologous and heterologous variant-specific neutralizing antibodies. Virology 185:2-9.
30. Lu, S., R. Wyatt, J. F. Richmond, F. Mustafa, S. Wang, J. Weng, D. C. Montefiori, J. Sodroski, and H. L. Robinson. 1998. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V 1/2 and V3 regions. AIDS Res. Hum. Retrovir. 14:151-155.
31. Mascola, J. R., M. K. Louder, T. C. VanCott, C. V. Sapan, J. S. Lambert, L. R. Muenz, B. Bunow, D. L. Birx, and M. L. Robb. 1997. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71:7198-7206.
32. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Reefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutehan, D. S. Burke, et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
33. Maseola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Haves, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
34. McGuire, T. C., L. K. Norton, K. I. O'Rourke, and W. P. Cheevers. 1988. Antigenic variation of neutralization-sensitive epitopes of caprine arthritis-encephalitis lentivirus during persistent arthritis. J. Virol. 62:3488-3492.
35. Montefiori, D. C., B. S. Graham, J. Zhou, R. A. Bucco, D. H. Schwartz, L. A. Cavacini, M. R. Posner, et al. 1993. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Investig. 92:840-847.
36. Moore, J., and A. Trkola. 1997. HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Res. Hum. Retrovir. 13:733-736.
37. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C.F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
38. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
39. Nara, P. L., R. R. Garrity, and J. Goudsmit. 1991. Neutralization of HIV-1: a paradox of humoral proportions. FASEB J. 5:2437-2455.
40. Narayan, O., J. E. Clements, J. D. Strandberg, L. C. Cork, and D. E. Griffin. 1980. Biological characterization of the virus causing leukoencephalitis and arthritis in goats. J. Gen. Virol. 50:69-79.
41. Nishimura, Y., T. Igarashi, N. Haigwood, R. Sadjadpour, R. J. Plishka, A. Buckler-White, R. Shibata, and M. A. Martin. 2002. Determination of a statistically valid neutralization tiler in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76:2123-2130.
42. Nyambi, P. N., M. K. Gorny, L. Bastiani, G. van der Groen, C. Williams, and S. Zolla-Pazner. 1998. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 72:9384-9391.
43. Özyörük, F., W. P. Cheevers, G. A. Hullinger, T. C. McGuire, M. Hutton, and D. P. Knowles. 2001. Monoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera. Clin. Diagn. Lab. Immunol. 8:44-51.
44. Page, M., C. Vella, T. Corcoran, P. Dilger, C. Ling, A. Heath, and R. Thorpe. 1992. Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS. AIDS 6:441-446.
45. Pantophlet, R., I. A. Wilson, and D. R. Burton. 2003. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77:5889-5901.
46. Parren, P. W., I. Mondor, D. Naniche, H. J. Ditzel, P. J. Klasse, D. R. Burton, and Q. J. Sattentau. 1998. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72:3512-3519.
47. Poignard, P., P. J. Klasse, and Q. J. Sattentau. 1996. Antibody neutralization of HIV-1. Immunol. Today 17:239-246.
48. Quinones-Kochs, M. I., L. Buonocore, and J. K. Rose. 2002. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 76:4199-4211.
49. Reitter, J. N., R. E. Means, and R. C. Desrosiers. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:679-684.
50. Saltarelli, M., G. Querat, D. A. Konings, R. Vigne, and J. E. Clements. 1990. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virology 179:347-364.
51. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
52. Skraban, R., S. Matthiasdottir, S. Torsteinsdottir, G. Agnarsdottir, B. Gudmundsson, G. Georgsson, R. H. Meloen, O. S. Andresson, K. A. Staskus, H. Thormar, and V. Andresdottir. 1999. Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype. J. Virol. 73:8064-8072.
53. Steimer, K. S., and N. L. Haigwood. 1991. Importance of conformation on the neutralizing antibody response to HIV-1 gp120. Biotechnol. Ther. 2:63-89.
54. Steimer, K. S., C. J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 254:105-108.
55. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
56. Valas, S., C. Benoit, C. Baudry, G. Perrin, and R. Z. Mamoun. 2000. Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoprotein. J. Virol. 74:6178-6185.
57. VanCott, T. C., F. R. Bethke, D. S. Burke, R. R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:4100-4110.
58. VanCott, T. C., J. R. Mascola, R. W. Kaminski, V. Kalyanaraman, P. L. Hallberg, P. R. Burnett, J. T. Ulrich, D. J. Rechtman, and D. L. Birx. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319-4330.
59. Wyatt, R., E. Desjardin, U. Olshevsky, C. Nixon, J. Binley, V. Olshevsky, and J. Sodroski. 1997. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J. Virol. 71:9722-9731.
60. Xu, W., R. Hofmann-Lehmann, H. M. McClure, and R. M. Ruprecht. 2002. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 20:1956-1960.
61. Zolla-Pazner, S., M. Lubeck, S. Xu, S. Burda, R. J. Natuk, F. Sinangil, K. Steimer, R. C. Gallo, J. W. Eichberg, T. Matthews, and M. Robert-Guroff. 1998. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72:1052-1059.